[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials

Recently, Changzhou Qianhong Bio-Pharma targeted anti-cancer Class 1 new drug QHRD110 capsules was approved for clinical trials.

Shanghai Medicilon provided a complete set of preclinical research services including drug efficacy, pharmacokinetics and safety evaluation, as well as registration and declaration services in the research and development of QHRD110 capsules to help the project succeed Clinically approved.

As a new small molecule CDK4/6 inhibitor independently developed by Qianhong with independent intellectual property rights, the proposed indication is advanced malignant solid tumors. QHRD110 capsules specifically inhibit CDK4/6, thereby arresting the cell cycle in the G1/S phase, and finally inhibiting the proliferation of tumor cells.

Medicilon is honored to participate in the pharmacology research, pharmacokinetic research, safety evaluation, and registration application project of Qianhong’s QHRD110.

Based on years of rich experience in non-clinical evaluation research, Medicilon scientifically and rigorously designed preclinical research trials according to the characteristics and declaration requirements of QHRD110 capsules, and finally completed various trial tasks with quality and quantity, laying the foundation for the successful approval of the project. solid foundation.

Medicilon hope that QHRD110 will obtain clinical approval, bring more hope of survival to more patients with advanced malignant solid tumors.